Morgan Stanley downgraded AlloVir to Equal Weight from Overweight with a price target of $1, down from $20, after the company decided to stop further posoleucel development due to futility following a pre-planned DSMB review of multiple ongoing Phase 3 studies. Management plans to analyze the data, but given the disappointing results across all three studies, the firm believes further development is unlikely and given uncertainty related to continued development the firm has removed all revenues from its model.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALVR:
- AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
- AlloVir reports Q3 EPS (39c), consensus (42c)
- ALVR Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue